A carregar...
Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
OBJECTIVE: To assess the efficacy and safety of dapagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, compared with placebo in patients with type 2 diabetes (T2D), documented pre-existing cardiovascular disease (CVD), and a history of hypertension. RESEARCH DESIGN AND METHODS: Patient...
Na minha lista:
| Publicado no: | Diabetes Care |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Diabetes Association
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4831907/ https://ncbi.nlm.nih.gov/pubmed/25852208 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc14-0315 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|